What is a Whitepaper?
A Whitepaper is an informative document, usually published by a company, that presents a detailed analysis of a specific topic, problem, or solution often with the goal of educating the reader by providing facts and evidence to persuade them to take a specific action.
The GLP-1 Whitepaper
"Maximizing the Promise of GLP-1 Medications: Partnering with Ideal Protein" is authored by the Ideal Protein Scientific Advisory Board. It explores how Ideal Protein complements GLP-1 medications to improve patient outcomes.
Value Proposition
- Educates medical providers on the benefits of combining Ideal Protein with GLP-1 treatments
- Builds trust by showcasing leadership and medical staff support
- Positions Ideal Protein as thought leaders in the weight management space
- Serves as a direct outreach tool to expand referral networks
- Increases brand awareness and promotes education on the care gap for medical providers
Where to Access:
The Whitepaper can be found in the GLP-1 Toolkit: Click for link
Implementation Guide
- Understand the Whitepaper: Start by reviewing the Whitepaper to understand how the Ideal Protein GLP-1 partnership benefits both clients and providers. Key highlights are listed below.
- Outreach to Providers: Use the customizable Whitepaper Provider letter to contact providers in your referral network, educate them on the Whitepaper, and suggest they read the full version. Remember to follow up.
- Post the Link on Your Website: Add the Whitepaper link as a valuable resource for both providers and clients.
- Share on LinkedIn: Like and share Ideal Protein's LinkedIn posts about the Whitepaper from the corporate page, Scientific Advisory Board Member pages, and IP Staff pages. Sharing with your network will help broaden the audience
Optional Suggested Readings
- From Molecules to Milestones: Reinventing the Future of Weight Loss Drugs (PWC Trends and Impact Survey)
- Real-World Trends in GLP-1 Treatment Persistence and Prescribing for Weight Management (Blue Shield Blue Cross)
- Many Patients Quit Taking GLP-1 Drugs: Understanding Why Is Key (TCMD)
Training & Support
For further information or assistance with using the GLP-1 Whitepaper, reach out to your Account Manager or email clientcare@idealprotein.com.
Key Highlights of the Whitepaper
GLP-1 Medications Overview
- GLP-1s (e.g., Ozempic, Wegovy, Zepbound) are revolutionary in obesity treatment, helping regulate blood sugar, suppress appetite, and promote weight loss.
- While originally developed for Type 2 diabetes, newer versions have been FDA-approved for obesity, showing additional benefits like cardiovascular improvements and better liver function.
- GLP-1 usage has grown rapidly, with 12% of the U.S. population having used them, but challenges like supply shortages and high costs persist.
Challenges with GLP-1s
- High costs (up to $1,349 per month) and limited insurance coverage for obesity treatment make affordability a significant issue.
- Side effects include gastrointestinal problems, muscle loss, and potential severe risks like dehydration and vitamin deficiencies.
- Weight regain after discontinuation is common, with research showing most users regain two-thirds of lost weight within a year.
- 30% of patients prescribed GLP-1s stop taking them within 30 days. (Blue Cross Blue Shield May 2024)
- 12 months after prescription - only 32% of patients still utilizing the medications (Gleason, July 2024)
Market and Industry Trends
- The GLP-1 market is expanding rapidly, with projections of $126 billion in sales by 2029.
- Research into new medications, including oral GLP-1s and combination therapies, is underway to improve accessibility and efficacy.
Ideal Protein's Role
- Ideal Protein, founded in 2004, offers a protein-first, low-carb diet that complements GLP-1 medications by reducing side effects and enhancing their benefits.
- Ideal Protein's approach can mitigate muscle loss and reduce risks like hypoglycemia by supporting a balanced diet rich in protein and micronutrients.
- The coaching component of Ideal Protein provides ongoing behavioral support, helping patients adopt long-term healthy habits, reducing the likelihood of weight regain after stopping GLP-1s.
Long-Term Success
- Nearly two-thirds of weight lost with GLP-1 is regained within one year after discontinuation
- Combining GLP-1 medications with Ideal Protein's nutritional protocols and coaching can address the "GLP-1 care gap," ensuring sustained weight loss and metabolic health.
- The collaboration between Ideal Protein and clinicians can enhance patient adherence and improve the overall effectiveness of GLP-1 treatment for lasting results.